We believe that Johnson & Johnson is positioned for solid growth, driven by strength of its pharmaceuticals business, recovery in the consumer segment and market stabilization coupled with share gain in medical devices and diagnostics.
On May 20, Johnson & Johnson (ticker: JNJ) (rated at Outperform) will host its biannual Pharmaceutical Analyst meeting. The pharmaceutical division represents Johnson & Johnson’s largest business segment and has been the key sales-growth driver for Johnson & Johnson in recent years, contributing 43% of total revenue and 56% of operating profits in 2014.
Hey, check out all the research scientist jobs. Post your resume today!
